Evidence map›Paper›PMID 40547706›Full record

ArticleACS omega2025

In Silico Discovery of a Novel Antiviral Scaffold for SARS-CoV‑2 Targeting the Spike Glycoprotein through the Fatty Acid Binding Pocket.

Luís Queirós-Reis, Mari Kaarbo̷, Huda Al-Baldawi, Rui Alvites, Ana Colette Maurício, Andrea Brancale, Marcella Bassetto, João R Mesquita

Abstract read
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Luís Queirós-ReisAbel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, Porto 4050-313, Portugal.ORCID https://orcid.org/0000-0002-5204-5046
Mari Kaarbo̷Department of Microbiology, Oslo University Hospital, Oslo 0424, Norway.
Huda Al-BaldawiDepartment of Microbiology, University of Oslo, Oslo 0316, Norway.
Rui AlvitesAbel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, Porto 4050-313, Portugal.
Ana Colette MaurícioAbel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, Porto 4050-313, Portugal.
Andrea BrancaleUniversity of Chemistry and Technology, Prague, 166 28 Praha, Czechia.ORCID https://orcid.org/0000-0002-9728-3419
Marcella BassettoSchool of Pharmacy and Pharmaceutical Sciences, College of Biomedical and Life Sciences, Cardiff University, Cardiff CF10 3BN, U.K.ORCID https://orcid.org/0000-0002-2491-5868
João R MesquitaAbel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, Porto 4050-313, Portugal.ORCID https://orcid.org/0000-0001-8769-8103

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The key viral protein for infection by SARS-CoV-2 is the spike glycoprotein (S protein), mediating entry into host cells, which therefore represents a strong focus for the development of targeted therapeutics. In this work, we explored the fatty acid binding pocket within the S protein, which stabilizes an inactive conformation and disrupts cell recognition and infection. To explore the potential of this site as a drug target, molecular dynamics simulations were performed, followed by a docking-based virtual screening of commercial druglike compounds. This in silico procedure enabled the identification of potential inhibitors of SARS-CoV-2 cell infection, likely by stabilizing an inactive spike conformation, detected in binding assays, although further experiments are required to directly confirm this action. The antiviral effect of the virtual hits was analyzed in cell-based assays, and one molecule displayed a low micromolar activity. Starting from the best antiviral compound found, structural analogues were purchased and evaluated in antiviral assays. An increase in activity was observed for multiple analogues, with the strongest antiviral compound showing submicromolar activity and low cytotoxicity. The successful identification of a new antiviral scaffold through in silico studies might pave the way for the further development of antivirals against SARS-CoV-2 and shows the reliability of the methodologies applied.

Identifiers

PMID40547706
PMCPMC12177760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.